Oncternal Therapeutics Inc

ONCT NASDAQ
4.580
+0.180
+4.09%
已收盘, 16:00 07/19 EDT
开盘
4.550
昨收
4.400
最高
4.590
最低
4.400
成交量
2.62万
成交均量(3M)
16.36万
52周最高
179.20
52周最低
4.380
换手率
0.17%
市值
7,039.38万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Oncternal Therapeutics Inc ONCT股票价格,Oncternal Therapeutics Inc股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.
展开 >

最近浏览

名称
价格
涨跌幅